These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 5911788)

  • 1. Treatment of haemophilia with purified factor 8 (FI-O-Ta).
    de Tezanos Pinto M
    Hemostase; 1966; 6(1):65-71. PubMed ID: 5911788
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of haemophilia.
    Br Med J; 1967 Apr; 2(5544):65-6. PubMed ID: 6020849
    [No Abstract]   [Full Text] [Related]  

  • 3. Haemophilia.
    Dormandy KM; Currey HL
    Rep Rheum Dis; 1970 Oct; 42():1-2. PubMed ID: 5493731
    [No Abstract]   [Full Text] [Related]  

  • 4. A method for the production of AHG rich cryoprecipitates & their use in the management of bleeding episodes in haemophilia.
    Kwa SB; Chen YF
    Singapore Med J; 1968 Mar; 9(1):12-6. PubMed ID: 5659889
    [No Abstract]   [Full Text] [Related]  

  • 5. The management of haemophilia.
    Rizza CR
    Practitioner; 1970 Jun; 204(224):763-72. PubMed ID: 5452203
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of haemophilia A with purified factor 8 obtained from human plasma by cryoprecipitation.
    Meyer K; Eernisse JG; Veltkamp JJ; Hemker HC; Loeliger EA
    Folia Med Neerl; 1967; 10(2):49-60. PubMed ID: 6039247
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic value of cryoprecipitate in hemophilia A].
    Lopaciuk S; Szczepański M; Klenowska Z; Daszyński J; Pawelski S
    Pol Tyg Lek; 1969 Jun; 24(22):829-32. PubMed ID: 4895749
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnosis and treatment of the hemophilias.
    Levin J
    Md State Med J; 1968 Sep; 17(9):75-7. PubMed ID: 5681701
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylactic therapy in classical hemophilia: a preliminary report.
    Robinson PM; Tittley P; Smiley RK
    Can Med Assoc J; 1967 Sep; 97(11):559-61. PubMed ID: 6050888
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent trends in the management of hemophilia.
    Dubey SM; Agarwal KN
    Indian Pediatr; 1974 May; 11(5):359-65. PubMed ID: 4426664
    [No Abstract]   [Full Text] [Related]  

  • 12. Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.
    Ehrenforth S; Kreuz W; Funk M; Auerswald G; Scharrer I
    Thromb Haemost; 1994 Nov; 72(5):784-5. PubMed ID: 7900088
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemofil and other factor VIII concentrates.
    Med Lett Drugs Ther; 1969 Nov; 11(23):96. PubMed ID: 5375104
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antihemophilic activity of donor blood].
    Shuruev AS
    Probl Gematol Pereliv Krovi; 1976; 21(9):45-6. PubMed ID: 1005391
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cellular immunology status in 5 hemophilic patients with inhibitors subjected to massive therapy with factor VIII concentrate].
    Aznar JA; Jorquera JI; González Molina A; Carbonell F; Trenor A; Sánchez Cuenca JM; de Andrés R
    Sangre (Barc); 1983; 28(5):663-4. PubMed ID: 6420915
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current status of the preparation and use of antihemophilic fractions in France. (Their use in surgery in hemophilia)].
    Ménaché D; Josso F; Steinbuch M; Soulier JP
    Transfusion (Paris); 1966; 9(3):237-44. PubMed ID: 5969559
    [No Abstract]   [Full Text] [Related]  

  • 18. [Safe and cost-conscious supply of factor-VIII-deficient Swiss hemophiliacs with AHF preparations].
    Stampfli K
    Ther Umsch; 1977 Oct; 34(10):717-24. PubMed ID: 918896
    [No Abstract]   [Full Text] [Related]  

  • 19. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HTLV-III, haemophilia and blood transfusion.
    Mitchell VE; Martin C; Flower AJ
    Br Med J (Clin Res Ed); 1985 Jul; 291(6489):213. PubMed ID: 2990635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.